QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development
QuidelOrtho (NASDAQ: QDEL) has appointed Erich Wolff as Executive Vice President of Strategy & Corporate Development, reporting to CEO Brian Blaser. Wolff brings over 20 years of leadership experience in healthcare, diagnostics, and MedTech sectors.
Previously serving as Buyouts Lead at Partners Group ($174B AUM), Wolff held senior roles at BD and Medtronic. At Medtronic, he revitalized the global diabetes business and managed corporate development for $11.5B neurosciences and diabetes units. At BD, he led key transactions including the embecta spinoff and $1.5B Parata Systems acquisition.
QuidelOrtho (NASDAQ: QDEL) ha nominato Erich Wolff Executive Vice President of Strategy & Corporate Development, che riporter脿 al CEO Brian Blaser. Wolff vanta oltre 20 anni di esperienza dirigenziale nei settori healthcare, diagnostica e MedTech.
In precedenza responsabile dei Buyouts presso Partners Group (con $174 miliardi di AUM), Wolff ha ricoperto posizioni senior in BD e Medtronic. In Medtronic ha rilanciato il business globale per il diabete e gestito lo sviluppo corporate per le divisioni neuroscienze e diabete dal valore di $11,5 miliardi. In BD ha guidato operazioni rilevanti, tra cui lo spin-off di embecta e l鈥檃cquisizione di Parata Systems per $1,5 miliardi.
QuidelOrtho (NASDAQ: QDEL) ha nombrado a Erich Wolff Executive Vice President of Strategy & Corporate Development, quien reportar谩 al CEO Brian Blaser. Wolff aporta m谩s de 20 a帽os de experiencia directiva en los sectores de salud, diagn贸stico y MedTech.
Anteriormente como Buyouts Lead en Partners Group (con $174.000 millones en activos bajo gesti贸n), Wolff ocup贸 cargos s茅nior en BD y Medtronic. En Medtronic revitaliz贸 el negocio global de diabetes y gestion贸 el desarrollo corporativo de las unidades de neurociencias y diabetes por $11.500 millones. En BD dirigi贸 transacciones clave, incluyendo la escisi贸n de embecta y la adquisici贸n de Parata Systems por $1.500 millones.
QuidelOrtho (NASDAQ: QDEL)电� Erich Wolff毳� 鞝勲灥 氚� 旮办梾臧滊皽 雼措嫻 靾橃劃攵�靷灔(Executive Vice President of Strategy & Corporate Development)鞙茧 鞛勲獏頄堨溂氅�, 攴傅鐢 CEO Brian Blaser鞐愱矊 氤搓碃頃╇媹雼�. Wolff电� 項姢旒�鞏�, 歆勲嫧 氚� MedTech 攵勳暭鞐愳劀 20雲� 鞚挫儊鞚� 毽崝鞁� 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
鞚挫爠鞐惖鐢 鞛愳偘鞖挫毄鞎� 1,740鞏� 雼煬鞚� Partners Group鞐愳劀 Buyouts Lead毳� 鞐瀯頄堦碃, BD鞕� Medtronic鞐愳劀 瓿犾渼歆侅潉 毵§晿鞀惦媹雼�. Medtronic鞐愳劀电� 旮�搿滊矊 雼闺嚚氤� 靷梾鞚� 鞛櫆靹表檾頃橁碃 115鞏� 雼煬 攴滊鞚� 鞁犼步瓿柬暀 氚� 雼闺嚚氤� 攵�氍胳棎 雽�頃� 旮办梾臧滊皽鞚� 齑濌磩頄堨姷雼堧嫟. BD鞐愳劀电� embecta 攵勳偓 氚� 15鞏� 雼煬 攴滊鞚� Parata Systems 鞚胳垬 霌� 欤检殧 瓯半灅毳� 欤茧弰頄堨姷雼堧嫟.
QuidelOrtho (NASDAQ: QDEL) a nomm茅 Erich Wolff Executive Vice President of Strategy & Corporate Development, qui rel猫vera du CEO Brian Blaser. Wolff apporte plus de 20 ans d鈥檈xp茅rience en direction dans les secteurs de la sant茅, du diagnostic et du MedTech.
Auparavant Buyouts Lead chez Partners Group (174 milliards de dollars d鈥檃ctifs sous gestion), Wolff a occup茅 des postes seniors chez BD et Medtronic. Chez Medtronic, il a relanc茅 l鈥檃ctivit茅 mondiale diab猫te et pilot茅 le d茅veloppement corporate des divisions neurosciences et diab猫te, repr茅sentant 11,5 milliards de dollars. Chez BD, il a dirig茅 des op茅rations cl茅s, notamment le spin-off d鈥檈mbecta et l鈥檃cquisition de Parata Systems pour 1,5 milliard de dollars.
QuidelOrtho (NASDAQ: QDEL) hat Erich Wolff zum Executive Vice President of Strategy & Corporate Development ernannt; er wird an CEO Brian Blaser berichten. Wolff bringt mehr als 20 Jahre F眉hrungserfahrung in den Bereichen Healthcare, Diagnostik und MedTech mit.
Zuvor war er Buyouts Lead bei Partners Group (mit 174 Mrd. USD verwaltetem Verm枚gen) und hatte leitende Positionen bei BD und Medtronic inne. Bei Medtronic belebte er das globale Diabetesgesch盲ft und verantwortete die Corporate Development-Aktivit盲ten f眉r die Neurowissenschafts- und Diabetes-Einheiten im Umfang von 11,5 Mrd. USD. Bei BD f眉hrte er wichtige Transaktionen, darunter den Spin-off von embecta und die 脺bernahme von Parata Systems f眉r 1,5 Mrd. USD.
- Strategic hire brings extensive M&A and business development expertise in healthcare sector
- Executive's track record includes managing multi-billion dollar business units
- Experience in executing major transactions including acquisitions, spinoffs, and divestitures
- None.
Mr.聽Wolff brings over two decades of leadership experience in strategy, M&A and business development across the healthcare, diagnostics, and MedTech sectors. Most recently, he served as Buyouts Lead for MedTech and Life Sciences Tools & Diagnostics at Partners Group, a global private equity firm with
"Erich brings a rare combination of strategic vision, operational rigor and transaction expertise," said Brian聽Blaser, President and Chief Executive Officer, QuidelOrtho. "His ability to drive complex portfolio decisions and execute high-impact growth strategies will be invaluable as we continue to advance the power of diagnostics for a healthier future."
During his tenure at聽Medtronic, Mr. Wolff played a pivotal role in revitalizing the company's global diabetes business and later assumed expanded responsibility for corporate development across its
"I'm honored to join聽QuidelOrtho at such a pivotal time," said Mr. Wolff. "The Company has a compelling vision for the future of diagnostics, a strong global footprint and a culture of innovation. I look forward to working alongside Brian and the leadership team to shape and execute strategies that can accelerate growth and deliver long-term value to our stakeholders."
Mr.聽Wolff holds a Bachelor of Business Administration in Finance and Economics from the University of Wisconsin鈥揗ilwaukee.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit and follow QuidelOrtho on LinkedIn, Facebook and X.
About聽QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent in vitro diagnostics solutions that transform data into understanding and action for more people in more places every day.
By offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine,聽QuidelOrtho brings fast, accurate and reliable diagnostics when and where they are needed 鈥� from home to hospital, lab to clinic.
Building on its long history of innovation,聽QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
Investor Contact: Juliet Cunningham Vice President, Investor Relations | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications |
View original content to download multimedia:
SOURCE QuidelOrtho Corporation
FAQ
Who is the new EVP of Strategy & Corporate Development at QuidelOrtho (QDEL)?
What is Erich Wolff's previous experience before joining QuidelOrtho (QDEL)?
What will be Erich Wolff's responsibilities at QuidelOrtho (QDEL)?
What major transactions did Erich Wolff oversee at BD?
